The scope of AI diagnostics looks both exciting and promising, considering its growing usage for improved diagnostics, personalized treatment plans, and healthcare applications. According to Coherent Market Insights, the global artificial intelligence diagnostics industry is poised to exhibit a robust CAGR of 21.2% during the forecast period, totaling US$ 5,773.6 million by 2030.
GE Healthcare, Vuno Inc., Canon Medical Systems USA, CHC Healthcare Group, Digital Diagnostics, Aidoc, Milliman Inc., Lucid Health, Imbio, Qure.AI, and Canon Medical Systems are top manufacturers of AI diagnostic solutions. These companies are investing large amounts of research and development to create novel AI-based diagnostic tools to meet evolving medical needs.
New AI diagnostic tools are being constantly developed and approved. Prominent players are also employing tactics like acquisitions, partnerships, alliances, and collaborations to strengthen their expertise, expand their regional footprint, and boost their revenues.
In December 2024, GE Healthcare showcased novel innovations at the Radiological Society of North America’s 2024 annual meeting to drive precision care. The new offerings, including next-generation solutions and various AI-enabled technologies, are designed to streamline workflows and enhance efficiency. These innovations are aimed at improving clinical decisions and patient care.
In September 2024, Roche expanded its digital pathology open environment with the integration of over 20 advanced artificial intelligence algorithms from eight collaborators. These AI-based pathology solutions are intended to help clinicians enhance patient care and expand personalized healthcare in cancer research and diagnostics.
Factors Driving Artificial Intelligence Diagnostics Industry Growth
Some of the prominent factors driving growth of the artificial intelligence diagnostics industry include rising prevalence of chronic diseases and surging demand for efficient and cost-effective diagnostics solutions.
Over the years, there has been a spike in the prevalence of chronic diseases like cancer, diabetes, and neurological disorders. This has created high demand for efficient and accurate diagnostic tools like AI-based ones, and the trend will likely continue through 2030.
AI-based diagnostic tools can process large datasets to identify patterns and anomalies, leading to enhanced efficiency and patient outcomes. High adoption of these AI-powered diagnostic solutions is expected to people sales growth in the coming years.
Government and private agencies across the globe are heavily investing in AI healthcare research and development. This will likely inform industry growth during the assessment period.
Growing demand for personalized medicine to counter diseases like cancer is another key growth-shaping factor. Similarly, advancements in AI algorithms, data analytics, and deep learning will positively impact the AI diagnostics industry.
Regional Insights
North America is anticipated to retain its dominance in the global AI diagnostics industry during the forecast period. This is attributable to rising adoption of artificial intelligence (AI) and machine learning (ML) in disease identification and diagnostics. Moreover, heavy presence of leading AI-diagnostic solution providers and increasing new product launches and approvals are expected to propel industry expansion.
Asia Pacific is set to become a happy hunting ground for providers of AI diagnostic tools. This can be attributed to high chronic disease burden, increasing government initiatives and programs, and rising awareness about the benefits of AI in disease diagnosis and treatment.
